Sangpornsuk Naruepat, Rungpradubvong Voravut, Tokavanich Nithi, Srisomwong Sathapana, Ananwattanasuk Teetouch, Teerawongsakul Padoemwut, Kerr Stephen J, Suwanwalaikorn Mathurin, Jongnarangsin Krit, Chokesuwattanaskul Ronpichai
Center of Excellence in Arrhythmia Research, Cardiac Center, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok 10330, Thailand.
Division of Cardiovascular Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok 10330, Thailand.
Biomedicines. 2022 Nov 7;10(11):2838. doi: 10.3390/biomedicines10112838.
One of the most concerning adverse events related to the SARS-CoV-2 vaccination is arrhythmia. To ascertain the relationship between vaccination and arrhythmic events, we studied the occurrence of arrhythmia in patients with cardiac implantable electronic devices (CIEDs) before and after a SARS-CoV-2 vaccination. Patients with CIEDs aged ≥18 who visited the CIED clinic at King Chulalongkorn Memorial Hospital and Vajira hospital from August 2021 to February 2022 were included. Information about the SARS-CoV-2 vaccination and side effects was obtained. One hundred eighty patients were included in our study, which compared the incidence of arrhythmias in the 14 days post-vaccination to the 14 days before vaccination. The median age was 70 years. The number of patients who received one, two, and three doses of the vaccine was 180, 88, and 4, respectively. ChAdOx1 was the primary vaccine used in our institutes, accounting for 86% of vaccinations. The vaccination was significantly associated with a 73% increase incidence of supraventricular tachycardia (SVT). In an adjusted model, factors associated with the incidence of SVT were the post-vaccination period, female sex, increasing BMI, chronic kidney disease, and a history of atrial fibrillation. Increased ventricular arrhythmia (VA) episodes were also associated with the post-vaccination period, female sex, decreasing BMI, and chronic kidney disease, but to a lesser degree than those with SVT episodes. No life-threatening arrhythmia was noted in this study. In conclusion, the incidence of arrhythmia in patients implanted with CIEDs was significantly increased after the SARS-CoV-2 vaccination.
与新型冠状病毒疫苗接种相关的最令人担忧的不良事件之一是心律失常。为了确定疫苗接种与心律失常事件之间的关系，我们研究了心脏植入式电子设备（CIED）患者在新型冠状病毒疫苗接种前后心律失常的发生情况。纳入了2021年8月至2022年2月期间在朱拉隆功国王纪念医院和瓦吉拉医院CIED门诊就诊的年龄≥18岁的CIED患者。获取了有关新型冠状病毒疫苗接种及副作用的信息。我们的研究纳入了180名患者，比较了接种疫苗后14天与接种前14天心律失常的发生率。中位年龄为70岁。接受一剂、两剂和三剂疫苗的患者人数分别为180、88和4。ChAdOx1是我们机构使用的主要疫苗，占疫苗接种的86%。疫苗接种与室上性心动过速（SVT）发生率显著增加73%相关。在调整模型中，与SVT发生率相关的因素是接种疫苗后时期、女性性别、BMI增加、慢性肾病和房颤病史。室性心律失常（VA）发作增加也与接种疫苗后时期、女性性别、BMI降低和慢性肾病相关，但程度低于SVT发作。本研究中未观察到危及生命的心律失常。总之，新型冠状病毒疫苗接种后，植入CIED的患者心律失常发生率显著增加。
